A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in…

Overview of attention for article published in BMC Pharmacology and Toxicology, July 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Readers on

mendeley: 18 Mendeley

So far, Altmetric has seen 1 X post from an account with 906 followers.

New article: A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive… https://t.co/cYsR4M2ryA #liv

29 Jul 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.